Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2Terminated
NCT04222985Phase 1Updated Oct 25, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Genital Herpes
United States
Trial of Hypofractionated IMRT Boost Versus Conventional IMRT Boost for Localized High Risk Prostate CancerUnknown
NCT04239599NAUpdated Sep 29, 2022
Sponsor: Sunnybrook Health Sciences Centre
Prostate Cancer
SAR3419 in Acute Lymphoblastic LeukemiaTerminated
NCT01440179Phase 2Updated Sep 21, 2022
Sponsor: Sanofi
Acute Lymphocytic Leukaemia
United States, France
Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)Approved For Marketing
NCT04877132N/AUpdated Sep 19, 2022
Sponsor: Sanofi
Sphingomyelin Lipidosis
Eliglustat on Gaucher Disease Type IIIBCompleted
NCT03519646NAUpdated Sep 15, 2022
Sponsor: National Taiwan University Hospital
Gaucher Disease, Type III
Taiwan
Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant GliomaCompleted
NCT00687765Phase 1, Phase 2Updated Sep 14, 2022
Sponsor: Sanofi
Glioblastoma
United States
Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)Completed
NCT03359356Phase 2Updated Sep 13, 2022
Sponsor: Icahn School of Medicine at Mount Sinai
Alopecia Areata
United States
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsUnknown
NCT03634982Phase 1Updated Sep 1, 2022
Sponsor: Revolution Medicines, Inc.
Solid Tumors
United States
Growth and Development Study of Alglucosidase AlfaCompleted
NCT00486889Phase 4Updated Aug 26, 2022
Sponsor: Genzyme, a Sanofi Company
Pompe Disease · Glycogen Storage Disease Type II (GSD-II) · Acid Maltase Deficiency Disease
United States
Dupilumab in Severe Chronic Hand EczemaUnknown
NCT04512339Phase 2Updated Aug 23, 2022
Sponsor: University Medical Center Groningen
Hand Eczema
Netherlands
Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based SettingCompleted
NCT05048589Phase 2Updated Aug 23, 2022
Sponsor: Tor Biering-Sørensen
Influenza
Denmark
Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)Completed
NCT00256399NAUpdated Aug 15, 2022
Sponsor: University Hospitals Cleveland Medical Center
BPH · Erectile Dysfunction
United States
Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene ExpressionCompleted
NCT05154383Phase 4Updated Aug 8, 2022
Sponsor: Centre Hospitalier Annecy Genevois
Vaccine Reaction
France
Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)Completed
NCT03346434Phase 2, Phase 3Updated Jul 28, 2022
Sponsor: Regeneron Pharmaceuticals
Dermatitis, Atopic
United States, Germany, Poland, United Kingdom
Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal InsulinCompleted
NCT03798080Phase 3Updated Jul 19, 2022
Sponsor: Sanofi
Type 2 Diabetes Mellitus
China
Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)Completed
NCT03798054Phase 3Updated Jul 19, 2022
Sponsor: Sanofi
Type 2 Diabetes Mellitus
China, Malaysia, South Korea, Taiwan
KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic ImpairmentCompleted
NCT04166942Phase 1Updated Jul 18, 2022
Sponsor: Kadmon, a Sanofi Company
Hepatic Impairment
United States
Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 StudiesCompleted
NCT02536755Phase 3Updated Jul 15, 2022
Sponsor: Genzyme, a Sanofi Company
Gaucher Disease
Canada, Russia, Tunisia
A Digital Flu Intervention for People With Cardiovascular ConditionsCompleted
NCT04584645NAUpdated Jun 21, 2022
Sponsor: Evidation Health
Cardiovascular Diseases · Atrial Fibrillation · Abnormal Heart Rhythms · Cardiac Arrest
United States
Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma ParticipantsCompleted
NCT03387852Phase 2Updated Jun 14, 2022
Sponsor: Sanofi
Asthma
United States, Argentina, Chile, Mexico, Poland +3 more
Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia RheumaticaTerminated
NCT03600818Phase 3Updated Jun 10, 2022
Sponsor: Sanofi
Polymyalgia Rheumatica
United States, Argentina, Australia, Belgium, Canada +12 more
Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic DermatitisTerminated
NCT03738423Phase 2Updated Jun 10, 2022
Sponsor: Regeneron Pharmaceuticals
Atopic Dermatitis
United States, Australia, Canada, Czechia, Germany +6 more
Study to Determine the Dose, the Safety and Effectiveness of a New Drug, Modified Release rhTSH, in Patients With Multinodular GoiterCompleted
NCT00454220Phase 2Updated Jun 7, 2022
Sponsor: Genzyme, a Sanofi Company
Multinodular Goiter
United States, Brazil, Canada, Denmark, France +3 more
Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and AboveCompleted
NCT05406180N/AUpdated Jun 6, 2022
Sponsor: Sanofi
Influenza
South Korea
Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)Completed
NCT00042341Phase 2Updated May 27, 2022
Sponsor: Genzyme, a Sanofi Company
Leukemia, Lymphoblastic, Acute, Pediatric
United States

Previous page Next page